NASDAQ:AFMDAffimed Stock Price, Forecast & News

$3.45

+0.20 (+6.15 %)

(As of 06/2/2020 04:00 PM ET)

Add

Compare

Today's Range

$3.19

Now: $3.45▼

$3.48

50-Day Range

$1.98

MA: $2.44▼

$3.29

52-Week Range

$1.42

Now: $3.45▼

$3.74

Volume1.28 million shs

Average Volume981,802 shs

Market Capitalization$263.03 million

P/E RatioN/A

Dividend YieldN/A

Beta2.77

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company's products include AFM24, an innate cell-engaging bispecific antibody that treats patients suffering of EGFR expressing solid tumors; AFM26, which binds to B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its products also comprise AFM11, a T cell TandAb, which is in Phase 1 clinical trial in patients with relapsed CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product; and Genentech. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Affimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.00, Affimed has a potential upside of 189.9% from its current price of $3.45.
Amount of Analyst Coverage
Affimed has only been the subject of 1 research reports in the past 90 days.

2.9 Community Rank

Outperform Votes
Affimed has received 387 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Affimed has received 281 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Affimed has received 57.93% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Affimed and other stocks. Vote “Outperform” if you believe AFMD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AFMD will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Affimed does not currently pay a dividend.
Dividend Growth
Affimed does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Affimed insiders have not sold or bought any company stock.
Percentage Held by Institutions
50.88% of the stock of Affimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Affimed are expected to grow in the coming year, from ($0.63) to $0.07 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Affimed is -6.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Affimed is -6.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Affimed has a P/B Ratio of 6.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.61 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:AFMD

Previous Symbol

CUSIPN/A

CIK1608390

Webwww.affimed.com

Phone49-62-2167-4360

Debt

Debt-to-Equity Ratio0.01

Current Ratio3.01

Quick Ratio3.00

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$23.96 million

Price / Sales10.98

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.57 per share

Price / Book6.05

Profitability

EPS (Most Recent Fiscal Year)($0.56)

Net Income$-36,250,000.00

Net Margins-149.51%

Return on Equity-93.90%

Return on Assets-31.47%

Miscellaneous

Employees8,406

Outstanding Shares76,240,000

Market Cap$263.03 million

Next Earnings Date6/3/2020 (Estimated)

OptionableOptionable

Receive AFMD News and Ratings via Email

Sign-up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter.

Affimed (NASDAQ:AFMD) Frequently Asked Questions

How has Affimed's stock been impacted by COVID-19 (Coronavirus)?

Affimed's stock was trading at $1.82 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AFMD shares have increased by 89.6% and is now trading at $3.45. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Affimed?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Affimed.

When is Affimed's next earnings date?

Affimed is scheduled to release its next quarterly earnings announcement on Wednesday, June 3rd 2020. View our earnings forecast for Affimed.

How were Affimed's earnings last quarter?

Affimed NV (NASDAQ:AFMD) issued its quarterly earnings results on Tuesday, April, 28th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.18) by $0.01. The biopharmaceutical company earned $4.35 million during the quarter. Affimed had a negative return on equity of 93.90% and a negative net margin of 149.51%. View Affimed's earnings history.

What price target have analysts set for AFMD?

2 analysts have issued 12-month price objectives for Affimed's shares. Their forecasts range from $10.00 to $10.00. On average, they anticipate Affimed's stock price to reach $10.00 in the next year. This suggests a possible upside of 189.9% from the stock's current price. View analysts' price targets for Affimed.

Has Affimed been receiving favorable news coverage?

Press coverage about AFMD stock has been trending very negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Affimed earned a media sentiment score of -3.5 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutAffimed.

Who are some of Affimed's key competitors?

Some companies that are related to Affimed include Applied Therapeutics (APLT), Rocket Pharmaceuticals (RCKT), INDIVIOR PLC/S (INVVY), MacroGenics (MGNX), BioXcel Therapeutics (BTAI), Athenex (ATNX), Stoke Therapeutics (STOK), Endo International (ENDP), Amphastar Pharmaceuticals (AMPH), Rhythm Pharmaceuticals (RYTM), ImmunoGen (IMGN), NextCure (NXTC), Passage Bio (ORIC), Omeros (OMER) and Gossamer Bio (GOSS). View all competitors.

What other stocks do shareholders of Affimed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Affimed investors own include Novavax (NVAX), JetBlue Airways (JBLU), Sprint (S), American International Group (AIG), Viking Therapeutics (VKTX), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Lipocine (LPCN), Sangamo Therapeutics (SGMO) and Sorrento Therapeutics (SRNE).

Who are Affimed's key executives?

Affimed's management team includes the following people:

Dr. Adi Hoess, CEO, MD & Member of Management Board (Age 57)
Dr. Florian H. M. Fischer, MD, CFO & Member of Management Board (Age 51)
Dr. Wolfgang Fischer, MD, COO & Member of Management Board (Age 55)
Prof. Melvyn Little, Founder & Consultant
Dr. Martin Treder, Chief Scientific Officer (Age 49)

What is Affimed's stock symbol?

Affimed trades on the NASDAQ under the ticker symbol "AFMD."

Who are Affimed's major shareholders?

Affimed's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.85%), Stonepine Capital Management LLC (3.93%), Wellington Management Group LLP (3.76%), State Street Corp (1.56%), AQR Capital Management LLC (1.44%) and Geode Capital Management LLC (0.83%).

Which major investors are selling Affimed stock?

AFMD stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Stonepine Capital Management LLC, Telemetry Investments L.L.C., UBS Group AG, BlackRock Inc., Geode Capital Management LLC, Alpine Global Management LLC, and Invesco Ltd..

Which major investors are buying Affimed stock?

AFMD stock was acquired by a variety of institutional investors in the last quarter, including Los Angeles Capital Management & Equity Research Inc., State Street Corp, Jane Street Group LLC, AQR Capital Management LLC, SG Americas Securities LLC, Connor Clark & Lunn Investment Management Ltd., Lindbrook Capital LLC, and Parametric Portfolio Associates LLC.

How do I buy shares of Affimed?

Shares of AFMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Affimed's stock price today?

One share of AFMD stock can currently be purchased for approximately $3.45.

How big of a company is Affimed?

Affimed has a market capitalization of $263.03 million and generates $23.96 million in revenue each year. The biopharmaceutical company earns $-36,250,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Affimed employs 8,406 workers across the globe.

What is Affimed's official website?

The official website for Affimed is www.affimed.com.

How can I contact Affimed?

Affimed's mailing address is IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The biopharmaceutical company can be reached via phone at 49-62-2167-4360 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff